Combined therapy with PARP inhibitors and Wee1 inhibitors have been previously shown to induce replication stress, DNA damage, and checkpoint damage, with evidence of potential synergy in preclinical models of breast and ovarian cancer (Fang et al., 2019). Here, WEE1 is linked to ovarian carcinoma.